NCT00851344

Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo

A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis

Conditions

• Rhinitis, Allergic, Seasonal

Interventions

Type	Name	Description
DRUG	GSK835726 (10mg)	GSK835726 (10mg) tablet
DRUG	GSK835726 (50mg)	GSK835726 (50mg) tablet
DRUG	GSK835726 (100mg)	GSK835726 (100mg) tablet
DRUG	Cetirizine (10mg)	Cetirizine (10mg) tablet as positive control
OTHER	Placebo	Placebo to match active

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2009-02-25
• Last updated: 2016-11-07

Locations

1 site across 1 country: Germany